The Prescription Drug Price Relief Act of 2025 aims to lower prescription drug prices by ending government-granted monopolies for manufacturers.
The Prescription Drug Price Relief Act of 2025 establishes a process for the Secretary of Health and Human Services to review brand name drugs annually and determine if their prices are excessive. If a drug's price is deemed excessive, the Secretary can void government-granted exclusivities and issue open, non-exclusive licenses to allow other entities to manufacture and sell the drug at a lower price. The Act also mandates the creation of a public database detailing excessive drug price determinations and requires manufacturers to report drug pricing information annually.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.